Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05780463 | MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | PHASE3 | COMPLETED | 485 | — | — | Jun 11, 2021 | Jun 8, 2023 | Feb 5, 2024 | 105 | United States, Denmark +8 |
Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90.
Ordinal outcome with 7 mutually exclusive categories
| Arm | Type | Description |
|---|---|---|
| MP0420 plus SOC | EXPERIMENTAL | * MP0420 600 mg solution (4 vials of 15 mg/mL); administered by IV infusion * Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion |
| Placebo plus SOC | PLACEBO_COMPARATOR | * Placebo administered by IV infusion * Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion |
| Name | Type | Description |
|---|---|---|
| MP0420 | DRUG | MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains. |
| Placebo | DRUG | Commercially available 0.9% sodium chloride solution |
| Remdesivir | BIOLOGICAL | Antiviral agent |
Inclusion Criteria: Refer to the master protocol (NCT04501978) Exclusion Criteria: Refer to the master protocol (NCT04501978) Additional Exclusion Criteria: 1. Pregnant women 2. Nursing mothers 3. Women of child-bearing potential who are unwilling to acknowledge the strong advice to abstain from ...